Actinium Expands into Additional Offices in Metro Park in Edison

New offices will sustain development activities related to Iomab-B™ Phase 3, Actimab-A Phase 1/2 clinical trials and pipeline expansion.

On Jun 4, 2014

Actinium Pharmaceuticals, Inc., a bio pharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has added additional office space at 379 Thornall Street in Edison, while  continuing to maintain its corporate headquarters in New York City. The company currently has 8 employees at its Edison location and over the next 12 months, anticipates adding 5 to 10 more.

The new offices are a key step towards supporting several corporate initiatives, including the advancement of the companies lead clinical program Iomab™-B into a Phase 3 Pivotal trial and the ongoing Phase1/2 clinical programs for Actimab-A. In addition, they will support future growth opportunities as the company advances existing earlier stage programs in other cancer indications.

Commenting on the expansion, Kaushik J. Dave, PhD., President and CEO of Actinium Pharmaceuticals said, “The new offices will enable Actinium to accelerate our efforts to build a strong, highly focused biotechnology company with an experienced management team that is well-positioned to successfully advance products from clinical development through commercialization. Our new location will support not only the recent expansion of our clinical, regulatory and pharmaceutical development staff but also the addition of new personnel as the advancement of our pipeline of innovative targeted payload immunotherapeutics including Iomab-B and Actimab-A continues.”